Acute Alcoholic Hepatitis: New and Experimental Medications.

Severe alcohol-associated hepatitis (AH) is associated with high mortality and is rising in incidence but there are limited treatment options. Therapies being studied for AH include those targeting systemic cytokine-mediated inflammation, hepatic regeneration, reactive oxygen species, the microbiome, and genetics. Regenerative agents (such as granulocyte colony-stimulating factor, interleukin-22, and stem cell therapies) and therapies targeting the dysregulated microbiome hold the most promise and warrant larger trials. Manipulating the underlying genetics (eg, by gene editing of PNPLA3 or HSD17B13) is a lofty goal in personalized targeted therapy for AH but is many years from primetime.